InsiderTrades

Form 4 for BSX Boston Scientific

Accepted 2024-01-05 00:00:00 ET · period of report 2024-01-04 · accession 0001225208-24-000467 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2024-01-05 2024-01-04 BSX Mirviss Jeffrey B. EVP, Pres, Periph Intervent S - Sale+OE $58.40 -15.0K 56.6K -21% -$876.0K
D 2024-01-05 2024-01-04 BSX Mirviss Jeffrey B. EVP, Pres, Periph Intervent M - OptEx $16.31 +15.0K 71.6K +27% +$244.6K
D 2024-01-05 2024-01-04 BSX Mirviss Jeffrey B. EVP, Pres, Periph Intervent M - OptEx $0.00 -15.0K 15.2K -50% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2024-01-04 S D 15,000 $58.40 56,588 D — — (F2) Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $58.40 to $58.405, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
2 Common Common Stock 2024-01-04 M A 15,000 $16.31 71,588 D — —
3 Derivative Stock Option (Right to Buy) 2024-01-04 M D 15,000 $0.00 15,172 D $16.31 · — to 2025-02-23 15,000 Common Stock (F3) Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 23, 2016, the first anniversary of the date of grant.